Bellerophon Therapeutics Inc.'s inhaled nitric oxide seems poised to become a key add-on, orphan therapy in pulmonary arterial hypertension (PAH) and, if all goes well, could also end up the only approved therapy in pulmonary hypertension when associated with chronic obstructive pulmonary disease (COPD).